森田 伸也 (モリタ シンヤ)

Morita, Shinya

写真a

所属(所属キャンパス)

医学部 泌尿器科学教室 (信濃町)

職名

助教(有期)

その他の所属・職名 【 表示 / 非表示

  • 医学部

経歴 【 表示 / 非表示

  • 2009年04月
    -
    2011年03月

    荻窪病院

学歴 【 表示 / 非表示

  •  

    慶應義塾大学

免許・資格 【 表示 / 非表示

  • 医師免許

 

研究分野 【 表示 / 非表示

  • ライフサイエンス / 泌尿器科学

研究キーワード 【 表示 / 非表示

  • 腎移植

 

論文 【 表示 / 非表示

  • A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report

    Iwasawa T., Kosaka T., Morita S., Mikami S., Nakamura K., Hongo H., Nishihara H., Oya M.

    BMC Medical Genomics (BMC Medical Genomics)  15 ( 1 )  2022年12月

     概要を見る

    Background: Abnormalities in homologous recombination contribute to the aggressive nature of castration-resistant prostate cancer. Retinoblastoma transcriptional corepressor 1 (RB1) and breast cancer 2 (BRCA2) exist close to each other in the same chromosome, and the significance of their concurrent loss has become a hot topic in the field of cancer research. Case presentation: A 61-year-old man presented with a chief complaint of a mass on his head and was diagnosed as multiple bone metastases from prostate cancer. He was treated with standard medication, but he died 2 years 6 months after being diagnosed with prostate cancer. Simultaneous biallelic loss of RB1 and BRCA2 as well as a truncating mutation of tumor protein p53 (TP53) were revealed by genomic analysis. Conclusion: To our knowledge, this is the first report of castration-resistant prostate cancer (CRPC) with BRCA2 and RB1 co-loss and TP53 mutation. To establish a treatment strategy for highly malignant cases with such multiple genetic features is important.

  • Endoscopic vaporization of benign prostatic hyperplasia using a contact 980 nm diode laser under antithrombotic therapy: A prospective survey

    Sanjo T., Tanaka N., Shinojima T., Yasumizu Y., Takeda T., Matsumoto K., Morita S., Kosaka T., Mizuno R., Asanuma H., Oya M.

    Asian journal of endoscopic surgery (Asian journal of endoscopic surgery)  15 ( 3 ) 585 - 590 2022年07月

     概要を見る

    INTRODUCTION: To prospectively clarify whether endoscopic contact laser vaporization of the prostate (CVP) can be safely performed even in patients undergoing antithrombotic therapy. METHODS: Fifty-five patients treated with CVP were enrolled. Patients were assigned to: (i) the antithrombotic therapy group (n = 21, 38%); or (ii) control group without antithrombotic therapy (n = 34, 62%). All patients in the antithrombotic therapy group continued all antithrombotic agents during the perioperative period and thereafter. RESULTS: No difference was noted in patient background between the two groups. In primary endpoints, decreases in the postoperative hemoglobin level were remarkable in the antithrombotic therapy group, while no serious effects were noted in either group. The control and antithrombotic therapy groups did not show a significant difference in the occurrence of catheter obstruction due to blood clots or serious hematuria following catheter removal. During follow-up, transurethral coagulation for hemostasis was needed only in the antithrombotic therapy group, with a frequency of transurethral coagulation of up to 14%. In secondary endpoints, no difference in the occurrence of perioperative or late-onset complications after surgery was noted between the two groups. Finally, no difference was noted in improvements in the International Prostate Symptom Score (IPSS), IPSS quality of life score, overactive bladder symptom score, maximum flow rate, or post-voiding residual urine volume between the two groups throughout the follow-up period. CONCLUSIONS: CVP can be performed safely and effectively in patients undergoing continuous antithrombotic therapy. However, the possibility of secondary bleeding after discharge in a subset of patients, such as those undergoing antithrombotic therapy, may be noted.

  • Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy

    Mizuno R., Takamatsu K., Yasumizu Y., Tanaka N., Takeda T., Morita S., Matsumoto K., Kosaka T., Asanuma H., Mikami S., Oya M.

    Urologia Internationalis (Urologia Internationalis)  2022年

    ISSN  00421138

     概要を見る

    Introduction: The aim of this retrospective study was to elucidate predictors of survival in metastatic renal cell carcinoma (mRCC) patients in an International Metastatic Renal Cell Carcinoma Database Consortium favorable risk group treated with frontline therapy without immune checkpoint inhibitors. Methods: A total of 238 patients with mRCC were reviewed. Among them, 55 patients in favorable risk group treated with single-agent systemic therapy were retrospectively analyzed. Clinical and pathological data were retrieved and analyzed retrospectively. The prognostic effect of each marker on overall survival (OS) was investigated with univariate and multivariate Cox's proportional hazards regression models. Results: After a median follow-up of 46.2 months after first-line treatment initiation, the median progression-free survival (PFS) was 29.3 months, and the median OS has not been reached. The estimated percentage of patients who were alive at 12 and 24 months were 96.1 and 94.1%, respectively. Multivariate analysis revealed that the long-term duration of first-line treatment (hazard ratio [HR]: 0.972, 95% confidence interval [CI]: 0.944-0.997, p = 0.0299) and the metastases limited to lung (HR: 3.852, 95% CI: 1.080-24.502, p = 0.0361) were independent predictors for longer OS in favorable risk mRCC patients. Conclusion: First-line systemic therapy for favorable risk mRCC patients with a single agent resulted in relatively longer PFS and OS. A longer duration of first-line treatment and lung only metastases are correlated with longer OS.

  • Predictors of renal function after adrenalectomy in patients with Cushing or subclinical Cushing syndrome

    Kufukihara R., Takeda T., Hakozaki K., Yasumizu Y., Tanaka N., Matsumoto K., Morita S., Kosaka T., Mizuno R., Asanuma H., Miyashita K., Kurihara I., Oya M.

    International Journal of Urology (International Journal of Urology)  2022年

    ISSN  09198172

     概要を見る

    Purpose: The postoperative course of renal function remains unclear in Cushing syndrome. We examined changes in renal function after adrenalectomy in patients with Cushing syndrome and attempted to identify predictors of renal impairment. Methods: The study population comprised 76 patients who underwent adrenalectomy for Cushing and subclinical Cushing syndrome between 2001 and 2018. Renal function and other factors were evaluated pre-operation, at 1 postoperative month, and 1 postoperative year. We defined a ≥10% decrease in the estimated glomerular filtration rate at 1 postoperative year as renal impairment, and predictors associated with this reduction were investigated. The relationship between renal function and steroid replacement after surgery was also examined. Results: Mean pre-operative estimated glomerular filtration rate was 82.2 ml/min/1.73 m2. While mean estimated glomerular filtration rate was significantly lower at 1 postoperative month than the pre-operative value (71.7 ml/min/1.73 m2 [89.1%], p < 0.001), no significant differences were observed between 1 postoperative year and pre-operation (79.5 ml/min/1.73 m2 [97.6%], p = 0.108). Twenty-six patients (34.2%) developed renal impairment. A multivariate analysis identified a low pre-operative adrenocorticotropic hormone level as an independent predictor of renal impairment (odds ratio 6.30, p = 0.031). Among 43 patients with available records of steroid replacement history, 18 (41.9%) developed renal impairment. The ratio of patients with a reduced steroid replacement dose at 1 postoperative month was significantly lower among patients with renal impairment than those without (22.2% vs. 56.0%, p = 0.027). Conclusions: The pre-operative adrenocorticotropic hormone level was a predictor of renal function after adrenalectomy in patients with Cushing or subclinical Cushing syndrome.

  • Hybridisation chain reaction-based visualisation and screening for lncRNA profiles in clear-cell renal-cell carcinoma

    Kufukihara R., Tanaka N., Takamatsu K., Niwa N., Fukumoto K., Yasumizu Y., Takeda T., Matsumoto K., Morita S., Kosaka T., Aimono E., Nishihara H., Mizuno R., Oya M.

    British Journal of Cancer (British Journal of Cancer)  2022年

    ISSN  00070920

     概要を見る

    Background: Analysis of long noncoding RNA (lncRNA) localisation at both the tissue and subcellular levels can provide important insights into the cell types that are important for their function. Methods: By applying new fluorescent in situ hybridisation technique called hybridisation chain reaction (HCR), we achieved a high-throughput lncRNA visualisation and evaluation of clinical samples. Results: Assessing 1728 pairs of 16 lncRNAs and clear-cell renal-cell carcinoma (ccRCC) specimens, three lncRNAs (TUG1, HOTAIR and CDKN2B-AS1) were associated with ccRCC prognosis. Furthermore, we derived a new lncRNA risk group of ccRCC prognosis by combining the expression levels of these three lncRNAs. Examining genomic alterations underlying this classification revealed prominent features of tumours that could serve as potential biomarkers for targeting lncRNAs. We then derived combination of HCR with expansion microscopy and visualised nanoscale-resolution HCR signals in cell nuclei, uncovering intracellular colocalization of three lncRNA (TUG1, HOTAIR and CDKN2B-AS1) signals such as those located intra- or out of the nucleus or nucleolus in cancer cells. Conclusion: LncRNAs are expected to be desirable noncoding targets for cancer diagnosis or treatments. HCR involves plural probes consisting of small DNA oligonucleotides, clinically enabling us to detect cancerous lncRNA signals simply and rapidly at a lower cost.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

総説・解説等 【 表示 / 非表示

  • COVID-19感染を契機に勃起不全を来したと考えられる1例

    茂田 啓介, 森田 伸也, 荘所 一典, 安水 洋太, 田中 伸之, 武田 利和, 松本 一宏, 小坂 威雄, 水野 隆一, 浅沼 宏, 大家 基嗣

    日本性機能学会雑誌 ((一社)日本性機能学会)  37 ( 1 ) 21 - 22 2022年06月

    ISSN  1345-8361

  • 【専門性と多様性を両立させる! 泌尿器科外来ベストNAVI】腎性高血圧・腎血管性病変 腎動脈瘤

    森田 伸也

    臨床泌尿器科 ((株)医学書院)  76 ( 4 ) 269 - 271 2022年04月

    ISSN  0385-2393

     概要を見る

    <文献概要>Point ▼偶発的に発見されることが多く,ほとんどが無症状である.▼高血圧を合併していることが多い.▼診断には,造影CTが有用である.▼治療は血管内治療と手術療法がある.

  • 【最新の不妊診療がわかる!-生殖補助医療を中心とした新たな治療体系】(第4章)生殖補助医療時代の一般不妊診療-検査や治療の意義と限界 男性不妊 検査 泌尿器科的診察・陰嚢超音波・CT/MRI

    大橋 正和, 森田 伸也, 高松 公晴

    臨床婦人科産科 ((株)医学書院)  76 ( 4 ) 250 - 254 2022年04月

    ISSN  0386-9865

     概要を見る

    <文献概要>▼不妊原因の約半数が男性サイドに存在する.泌尿器科医による男性不妊治療で,(1)精液所見が改善しART→IUI→タイミングといった婦人科不妊治療の"step down"が可能となる症例や,(2)性行為が可能となり自然妊娠が可能となる症例が多々ある.男性サイドに問題がある場合は,泌尿器科男性不妊専門医に積極的に紹介してほしい.▼男性不妊診療は,問診,身体診察,ホルモン採血,陰嚢超音波,CT・MRIなどの多角的なアプローチにより行われる.

  • 【急性腎不全(ARF)から急性腎障害(AKI)へ】腎後性AKIの診断と治療

    森田 伸也, 大家 基嗣

    日本医師会雑誌 ((公社)日本医師会)  151 ( 1 ) 47 - 50 2022年04月

    ISSN  0021-4493

  • 【専門性と多様性を両立させる! 泌尿器科外来ベストNAVI】腎性高血圧・腎血管性病変 腎血管性高血圧症

    森田 伸也

    臨床泌尿器科 ((株)医学書院)  76 ( 4 ) 262 - 264 2022年04月

    ISSN  0385-2393

     概要を見る

    <文献概要>Point ▼腎血管性高血圧(RVHT)は,全高血圧患者の約1%にみられる.▼原因としては,粥状動脈硬化性,線維筋性異形成(FMD)によるものが多い.▼診断には,腎動脈超音波検査,MRアンギオグラフィ(MRA),CTアンギオグラフィ(CTA)が有用である.▼治療は薬物療法が中心であるが,経皮的腎動脈形成術(PTRA)が適応となる場合もある.

全件表示 >>

研究発表 【 表示 / 非表示

  • 診断が困難であった前立腺肉腫の1例

    金子 剛、石田 勝、山崎恵一、森田伸也、越田竹朗、西本紘嗣郎、中島 淳、村井 勝、亀山香織、向井萬起男

    日本泌尿器科学会東京地方会 (東京) , 

    2006年07月

    口頭発表(一般)

  • ABO不適合生体腎移植後にCMVアンチゲネミア陽性をきたした2例

    香野日高、中川健、森田伸也、宮島哲、朝倉博孝、中島淳、村井勝

    第39回臨床腎移植学会 (鬼怒川) , 

    2006年01月

    口頭発表(一般)

  • 糖尿病性腎症による腎不全に対する高齢者腎移植の1例

    森田伸也、中川健、宮島哲、村井勝

    第39回臨床腎移植学会 (鬼怒川) , 

    2006年01月

    口頭発表(一般)

  • 後腹膜腔に発生し,膀胱の著明な圧迫を来した偽粘液腫の1例

    森田伸也,香野日高,篠島利明,大東貴志,村井勝

    第555回日本泌尿器科学会東京地方会 (東京) , 

    2002年07月

    口頭発表(一般)

競争的研究費の研究課題 【 表示 / 非表示

  • 移植腎長期生着へ向けた慢性移植腎症非免疫学的メカニズムの解明と予防法の開発

    2019年04月
    -
    2022年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 森田 伸也, 基盤研究(C), 補助金,  研究代表者

 

担当授業科目 【 表示 / 非表示

  • 泌尿器科学講義

    2022年度

  • 泌尿器科学講義

    2021年度

  • 泌尿器科学講義

    2020年度

  • 泌尿器科学講義

    2019年度